Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types.
Identifying these proteins may not only help determine patients’ prognoses but also point to potential therapeutic targets for investigators who are searching for new CLL treatments.
“The results offer a meaningful biological approach into the protein composition of CLL cells at an early stage of the disease, when the clinical characteristics of patients are similar and the course of the disease is difficult to predict. Our results showed that the protein profile can however predict how the disease will further evolve,” said lead author Cristina Bagacean, Ph.D., of CHU de Brest, in France. “This approach could identify putative therapeutic targets in order to prevent CLL progression.”
Cristina Bagacean et al, Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia, Journal of Leukocyte Biology (2021). DOI: 10.1002/JLB.4HI0620-392R
Scientists identify protein markers related to the most common form of leukemia (2021, July 21)
retrieved 21 July 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
Need Your Help Today. Your $1 can change life.